Compare VanEck Australian Floating Rate ETF (FLOT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Inovio Pharmaceuticals Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.96 (market cap $11.24B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: VanEck Australian Floating Rate ETF is far larger — about 100.2× Inovio Pharmaceuticals Inc's market cap, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FLOT | INO | |
|---|---|---|
Market Cap | $11.24B | $112.19M |
Volume | 1,872,962 | 3,201,278 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $2.60 |
52-Week Low | $50.72 | $0.66 |
Typical Hold Time | 21 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.96 with minimal daily movement (+0.1%) amid bearish technical signals. The ETF faces concentration risk with 47% bank exposure while benefiting from floating rate exposure during Fed tightening cycles. Recent dividend payments of $0.17-0.18 reflect current yield environment, though technical indicators show strong selling pressure with moving averages and ADX signaling bearish momentum.
The floating rate structure positions FLOT to benefit from continued Fed hawkishness, but high bank concentration presents sector-specific risks. Current technical weakness suggests near-term pressure, while the fund's yield advantage over cash equivalents remains attractive for income-focused investors in rising rate environments.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
